Sugi Predict

Sugi Predict / Compounds / SCHEMBL1760701

SCHEMBL1760701

SCHEMBL1760701

C#CCCCCCCCC#C

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CYP2D6 P10635 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ HSD17B10 Q99714 1/20 0.55
▸ CYP3A4 P08684 3/20 0.44
▸ USP2 O75604 3/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ MEN1 O00255 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ HLCS P50747 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2520528 1.00 MAPT (0.55) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL8382273 1.00 MAPT (0.55) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL1232553 1.00 MAPT (0.55) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL1760712 1.00 — —
SCHEMBL10481146 0.96 MAPT (0.52) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL1062616 0.95 — —
SCHEMBL973460 0.86 — —
SCHEMBL25167631 0.83 MAPT (0.44) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL23034430 0.83 CYP1A2 (0.44) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL22689611 0.83 CYP1A2 (0.44) MAPTCYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540073-B2 Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor BRILLIANT LIGHT POWER, INC. (US) 2026-02-03 — — US disclosed
CN-109666158-B Hybrid dynamic polymer and application thereof 厦门逍扬运动科技有限公司 2023-04-07 — — CN disclosed
US-20230045778-A9 HETEROGENEOUS HYDROGEN-CATALYST SOLID FUEL REACTION MIXTURE AND REACTOR BRILLIANT LIGHT POWER, INC. (US) 2023-02-09 — — US disclosed
US-11365183-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2022-06-21 — — US disclosed
US-20200299130-A1 HETEROGENEOUS HYDROGEN-CATALYST REACTOR BRILLIANT LIGHT POWER, INC. (US) 2020-09-24 — — US disclosed
US-20190315701-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2019-10-17 — — US disclosed
US-10287262-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2019-05-14 — — US disclosed
EP-3222612-A1 NOVEL EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2017-09-27 — — EP disclosed
EP-2376432-B1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) 2017-04-12 — — EP disclosed
US-20160326128-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2016-11-10 — — US disclosed
US-9272991-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2016-03-01 — — US disclosed
US-20120122972-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2012-05-17 — — US disclosed
EP-2376432-A1 NOVEL EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2011-10-19 — — EP disclosed
US-20110114075-A1 HETEROGENEOUS HYDROGEN-CATALYST REACTOR BRILLIANT LIGHT POWER, INC. 2011-05-19 — — US disclosed
EP-2318307-A2 HETEROGENEOUS HYDROGEN-CATALYST REACTOR Blacklight Power, Inc. (US) 2011-05-11 — — EP disclosed
WO-2010081683-A1 NOVEL EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (DE) 2010-07-22 — — WO disclosed
EP-2208720-A1 Novel eicosanoid derivatives Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2010-07-21 — — EP disclosed
WO-2010014684-A2 HETEROGENEOUS HYDROGEN-CATALYST REACTOR BLACKLIGHT POWER, INC. (US) 2010-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122972-A1 NOVEL EICOSANOID DERIVATIVES FABP3, PTGER3, PTGES3 MAPT 4873/4885CYP1A2 117/4885CYP2D6 241/4885
US-10287262-B2 Eicosanoid derivatives FABP3, PTGER3, PTGES3 MAPT 4861/4885CYP1A2 132/4885CYP2D6 276/4885
US-11365183-B2 Eicosanoid derivatives FABP3, PTGER3, PTGES3 MAPT 4861/4885CYP1A2 132/4885CYP2D6 276/4885
US-12540073-B2 Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor SCO2, SOD1, HAO2 MAPT 3595/4885CYP1A2 1592/4885CYP2D6 4019/4885
US-20160326128-A1 NOVEL EICOSANOID DERIVATIVES FABP3, PTGER3, PTGES3 MAPT 4864/4885CYP1A2 137/4885CYP2D6 287/4885
US-20190315701-A1 NOVEL EICOSANOID DERIVATIVES FABP3, PTGER3, PTGES3 MAPT 4864/4885CYP1A2 137/4885CYP2D6 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.